Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Trending With Impact: RNA Modification Regulatory Proteins in Melanoma

Oncotarget

May 20, 2021
Researchers analyzed various publicly available datasets and identified two RNA modification regulatory proteins that are not only upregulated in melanoma, but necessary for melanoma growth. continue reading »

Impact Journals to Present on Scientific Integrity at SSP Annual Meeting

Oncotarget

May 19, 2021
Impact Journals is an exhibitor/sponsor and will be presenting its scientific integrity process at the Society for Scholarly Publishing (SSP) Annual Meeting, occurring virtually from May 24-27, 2021. continue reading »

Tomivosertib Versus Acute Myeloid Leukemia

Oncotarget

May 12, 2021
In the cover paper chosen for Oncotarget’s Volume 12, Issue 10, researchers investigated the efficacy of Tomivosertib in pre-clinical models of acute myeloid leukemia (AML). continue reading »

Table of Contents: Oncotarget’s Volume 12, Issue #10

Oncotarget

May 12, 2021
Read the latest oncology-focused research published in this week’s issue of Oncotarget, Volume 12, Issue 10. continue reading »

Behind the Study: Extending Survival in Glioma Models

Oncotarget

May 11, 2021
Dr. Gregory Riggins from Johns Hopkins University discusses his 2017 study published by Oncotarget, entitled, "Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients." continue reading »